Stockreport

Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF The revenue forecast for next year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline. Investors have been pretty optimistic on [Read more]